He said the "future of Moderna is bright," noting that it now has three approved products and the potential for up to eight more in the next three years. In May, the Food and Drug Administration approved Moderna's third- ever product, a next-generation Covid shot. But Bancel said "this decision was not made lightly." Also in May, Moderna said it will reduce annual operating expenses by about $1.5 billion by 2027. That target adds to cuts that the company previously announced. Moderna will provide another up ...

Moderna(MRNA.O)上涨1.9%，美国食品药品监督管理局（FDA）批准该公司面向65岁及以上成人的下 一代新冠疫苗。 ...

Moderna(MRNA.O)盘前上涨4.3%，此前美国食品药品监督管理局（FDA）批准该公司面向65岁及以上 成人的下一代新冠疫苗。 ...